Redcare Pharmacy NV raised its 2026 revenue growth guidance to 15-17%, up from the previous 13-15%. The online pharmacy reported reaching 1.7 million active prescription customers in Germany, representing 4% quarter-over-quarter growth. The company's adjusted EBITDA margin improved to 3.5% in Q2, its highest level in a decade. This was achieved whilst reducing marketing spending, demonstrating improved cost efficiency. However, the German non-prescription business experienced growth deceleration, partly attributed to a heatwave and competitive pressures. July trading was softer than expected, with anticipated group growth below 20%. CEO Olaf Heinrich addressed concerns about competitor Rossmann entering the online pharmacy market, noting that previous entrant DM had limited impact. He emphasised the complexity of the prescription segment as a barrier to new competitors. A new regulation requiring personal signatures for prescription deliveries will add minimal costs, expected to be less than £1 million annually. The company was not cash flow positive in Q2 despite improved profitability.

Redcare Pharmacy N.V. / Key word(s): Bond Redcare Pharmacy: Redemption of 2021/2028 convertible bond. 19.12.2025 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement.